The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression
Emerging Minds Journal for Student Research January 25, 2026 Rishika Scott, James Smith
A systematic review and meta-analysis of seven studies (five open-label and two randomized controlled trials) found that a single 25 mg dose of psilocybin per clinical session is effective for treatment-resistant depression. The 25 mg dose significantly reduced depressive severity compared to 10 mg and 1 mg doses, with two-dose studies showing greater benefit than single-dose studies. The evidence suggests psilocybin is a promising therapeutic, though more research is needed due to limitations in the available studies.